New drug ATG-031 targets Hard-to-Treat cancers in first human trial
NCT ID NCT06028373
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This study tests an experimental drug called ATG-031 in people with advanced solid tumors or B-cell non-Hodgkin lymphomas that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. Participants receive ATG-031 by infusion every three weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental drug called ATG-031
- What this could lead to
- If successful, this could lead to a new treatment option for people with advanced solid tumors or B-cell non-Hodgkin lymphomas who have run out of standard therapies.
- What could go wrong
- This is an early Phase 1 trial with only 38 participants, so the drug may prove unsafe or ineffective. Side effects are unknown and could be severe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Regents of the University of Colorado
Aurora, Colorado, 80045, United States
-
University of California San Francisco (UCSF)
San Francisco, California, 94102, United States
-
University of Texas M.D. Anderson Cancer Center
Houston, Texas, 77030, United States
-
Yale University
New Haven, Connecticut, 06520- 8087, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could an AI-Designed pill take on Hard-to-Treat cancers?
- Can a new nucleotide analogue boost cancer treatment?
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
- Can a new antibody help the immune system fight advanced cancers?
- Can an experimental pill slow advanced solid tumors? a phase 1 trial puts HW221043 to the test.
- Can a cancer vaccine train the body to fight advanced tumors?